2023. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s143. DOI:https://doi.org/10.25251/skin.7.supp.143.